A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2001
10/18/2001	WO2001023388A3 AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
10/18/2001	WO2001020004A3 Protein phosphatase and kinase proteins
10/18/2001	WO2001017552A8 Kaposi's sarcoma-associated herpesvirus ks-sm gene product and uses thereof
10/18/2001	WO2001012803A3 Methods and compositions for restoring antibiotic susceptibility in glycopeptide-resistant enterococcus
10/18/2001	WO2001005971A9 Secreted polypeptides and corresponding polynucleotides
10/18/2001	WO2001004145A3 Glutx polypeptide family and nucleic acids encoding same
10/18/2001	WO2000073460A3 Modified cytokine for its stabilisation
10/18/2001	WO2000069898A8 Molecular interactions in allergy cells
10/18/2001	WO2000057837A9 Compositions and methods for effecting the levels of cholesterol
10/18/2001	WO2000046236A9 Novel rgs-containing molecules and uses thereof
10/18/2001	WO2000044782A9 Ewing's tumour antigen, nucleic acid and antibodies
10/18/2001	WO2000043026A3 Recombinant sp-a for the treatment or prevention of pulmonary infection and inflammation
10/18/2001	WO2000039283A9 Use of cd40 engagement to alter t cell receptor usage
10/18/2001	WO2000037635A3 Genetic suppressor elements against human immunodeficiency virus
10/18/2001	WO2000032233A3 Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
10/18/2001	WO2000020041A9 Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent
10/18/2001	US20010032339 Chaperone suppression of ataxin-1 aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1
10/18/2001	US20010032337 Introduction of exogenous nucleotide sequences into a genome by microinjection of infectious retrovirus into the perivitelline space of the egg; making a bovine embryo; use to confer disease resistance, for example
10/18/2001	US20010031877 Eprosartan dihydate and a process for its production and formulation
10/18/2001	US20010031873 Drug delivery, antitumor agents
10/18/2001	US20010031858 Coupling of 2-(2-acetylamino-3-(4-amidinophenyl) propionylamino)-2-cyclohexylacetic acid with a 3-(2-amino-2-carbamoylethyl)-1-methylpyridinium salt or a salt thereof; anticoagulants
10/18/2001	US20010031857 Memno peptides, process for their preparation and use thereof
10/18/2001	US20010031780 Compounds such as (s,s)1-(2-amino-3,3-dimethyl-butyryl)-2,5-dihydro-1h-pyrrole-2 -carbonitrile administered as antidiabetic agents; dipeptidyl peptidase-iv (dpp-iv)
10/18/2001	US20010031773 Administering (5-aryl-1,2,4-thiadiazol)-3-yl thiourea and urea derivatives to treat hepatitis, HIV and Kaposi sarcoma, as viricides and anticarcinogenic agents
10/18/2001	US20010031741 Methods for treatment of lysosomal storage diseases
10/18/2001	US20010031738 Administering antibody
10/18/2001	US20010031733 Compound B as angiogenic agent in combination with human growth factors
10/18/2001	US20010031731 Free radical scavengers or promoters thereof as therapeutic adjuvants in preterm parturition
10/18/2001	US20010031728 Fungicides
10/18/2001	US20010031727 Reducing oxygen concentration in aqueous solutions; antitumor agents, antiinflammatory agents
10/18/2001	US20010031726 Mixture of buffer, zinc, phenolic preservative and isotonic agent
10/18/2001	US20010031725 Polysaccharides
10/18/2001	US20010031724 Dominant selectable marker for gene transformation and disruption in yeasts
10/18/2001	US20010031721 Mixture with arginine; storage stability
10/18/2001	US20010031485 Nucleic acid coding for fusion protein which binds receptor; internalized by endocytosis; inhibits ribosomes and angiogenesis; therapy for tumors, metastasis, eye disorders, chronic inflammation and ischemic injuries
10/18/2001	US20010031476 Determining rate of bone resorption by measuring peptides in body fluid having 3-hydroxypyridinium cross-link; diagnostic tool for Paget's disease
10/18/2001	US20010031287 Plant extracts
10/18/2001	US20010031277 Water swellable, semipermeable material
10/18/2001	US20010031274 Biodegradable polymer
10/18/2001	US20010031263 Method and composition for treating paramyxovirus
10/18/2001	US20010031261 Use of genetically engineered antibodies to treat multiple myeloma
10/18/2001	US20010031260 Administering tumor necrosis factor antagonist; rheumatic diseases, skin disorders
10/18/2001	US20010031259 Novel methods and compositions for treatment of autoimmune diseases
10/18/2001	US20010031256 Vision defects
10/18/2001	US20010031252 Endogenous immune response
10/18/2001	DE10016083A1 Nicht-menschliches Tiermodell für Wachstumsdefizienz und Defekte der Informationsverarbeitung oder der kognitiven Funktion und seine Verwendung A non-human animal model for Wachstumsdefizienz and defects of the information processing or the cognitive function and its use
10/18/2001	DE10007234A1 Peptid und dafür kodierende Nukleinsäure zur Bestimmung, Diagnostik und Therapie von Erkrankungen des Nervensystems Peptide and nucleic acid coding for determining diagnosis and treatment of diseases of the nervous system
10/18/2001	CA2659656A1 The use of vegf165 to treat neuron disorders
10/18/2001	CA2654413A1 Use of vegf and homologues to treat neuron disorders
10/18/2001	CA2414652A1 Animal and cell models for type ii diabetes and their use
10/18/2001	CA2406485A1 Hpv-specific short-mers
10/18/2001	CA2406484A1 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
10/18/2001	CA2406370A1 Gpcr-proteins and nucleic acids encoding same
10/18/2001	CA2406352A1 Peptide conjugates for drug delivery
10/18/2001	CA2406233A1 Compositions for drug delivery
10/18/2001	CA2406128A1 Methods and compositions for treating neoplasms
10/18/2001	CA2406058A1 Tm4sf receptor polynucleotides, polypeptides, and antibodies
10/18/2001	CA2405912A1 Albumin fusion proteins
10/18/2001	CA2405907A1 Cxcr4 agonist treatment of hematopoietic cells
10/18/2001	CA2405870A1 Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia
10/18/2001	CA2405793A1 Combination of organic compounds
10/18/2001	CA2405779A1 Tamandarin and didemnin analogs and methods of making and using them
10/18/2001	CA2405568A1 Prion-binding peptidic ligands and methods of using same
10/18/2001	CA2405476A1 Compounds and methods for modulating endothelial cell adhesion
10/18/2001	CA2405311A1 Multiprotein-complexes comprising a nmda receptor and uses thereof
10/18/2001	CA2405291A1 Methods of using growth factors for treating heart disease
10/18/2001	CA2405124A1 Gene coding for erbin, and diagnostic and therapeutic uses thereof
10/18/2001	CA2405104A1 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
10/18/2001	CA2404988A1 Listeria monocytogenes genome, polypeptides and uses
10/18/2001	CA2404971A1 Human protein kinases and protein kinase-like enzymes
10/18/2001	CA2404889A1 Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
10/18/2001	CA2404644A1 Modulators of prorenin activity
10/18/2001	CA2404229A1 Human transporters and ion channels
10/18/2001	CA2404087A1 Combination product comprising a non-steroidal antiandrogen and an egfr tyrosine kinase inhibitor
10/18/2001	CA2403946A1 Genes expressed in foam cell differentiation
10/18/2001	CA2402790A1 Compositions and methods for promoting wound healing
10/18/2001	CA2402410A1 The high bone mass gene of 11q13.3
10/18/2001	CA2402392A1 Non-endogenous, constitutively activated known g protein-coupled receptors
10/18/2001	CA2401836A1 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
10/18/2001	CA2401290A1 Novel g protein-coupled receptor protein and dna thereof
10/17/2001	EP1146125A1 Poxvirus with targeted infection specificity
10/17/2001	EP1146122A2 Human G-protein chemokine receptor HDGNR10 (CCR5 receptor)
10/17/2001	EP1146121A1 Method for modification of proteins by transglutaminase
10/17/2001	EP1146056A1 Antibodies which activate an erythropoietin receptor
10/17/2001	EP1146055A2 Human G-protein chemokine receptor HDGNR10 (CCR5 receptor)
10/17/2001	EP1146054A1 ReL1A BINDING INHIBITOR, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF
10/17/2001	EP1146053A1 Meg-4 protein
10/17/2001	EP1145721A2 Human G-protein chemokine receptor HDGNR10 (CCR5 receptor)
10/17/2001	EP1145717A2 Synergistic effect of a sulfonylurea and/or non-sulfonylurea K plus ATP channel blocker, and a phosphodiesterase 3 type inhibitor
10/17/2001	EP1145644A2 Glycoprotein having inhibitory activity against helicobacter pylori colonization
10/17/2001	EP1144998A2 Neisseria genomic sequences and methods of their use
10/17/2001	EP1144997A2 Methods and compounds for modulating nuclear receptor activity
10/17/2001	EP1144690A1 Antisense modulation of cellular inhibitor of apoptosis-2 expression
10/17/2001	EP1144682A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
10/17/2001	EP1144678A2 Susceptibility to psoriasis
10/17/2001	EP1144654A2 Serine protease
10/17/2001	EP1144651A1 Polypeptides derived from jnk3
10/17/2001	EP1144650A2 Goodpasture antigen binding protein
10/17/2001	EP1144648A1 Cyclic nucleotide-associated proteins
10/17/2001	EP1144643A1 Neisseria meningitidis antigen

1 ... 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 2194 2195 2196 2197 2198 ... 3163